This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Latest analysis from the Cancer Research Institute of the global landscape of cellular immunotherapies, including R&D trends and real-world usage, highlights key challenges including effective solid tumor targeting, manufacturing complexities, and commercial access to approved therapies
Awareness and educational program offerings for cancer patients and caregivers about the latest advances in cancer immunotherapy shared over 30 days in June
First patients dosed in phase 2 platform clinical trial testing novel immunotherapy combinations in highly malignant ovarian cancer.
CRI’s latest analysis of the PD1/PDL1 immuno-oncology landscape confirms trends in trial design and patient enrollment, points to robust pipeline of new agents in clinical development
Four Key Scientists Behind the Vaccines to Share Virtual Stage at November 10 Event; Katalin Karikó, Ugur Sahin, Özlem Türeci, and Drew Weissman to Receive 2021 William B. Coley Award for Distinguished Research in Basic Immunology; Overdue Opportunity to Understand mRNA’s Origins and Future in Cancer Research
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).